Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.

被引：0

作者：

Ma, Fei

Luo, Suxia

Zhang, Bin

Ma, Qi

Ji, Sheqing

Zhang, Zhandong

Zhang, Yonglei

Yang, Wei

Peng, Liangqun

Guo, Dandan

Ren, Jinjun

Zhang, Yuan

Su, Yueyue

Li, Jing

Liu, Wentao

Huang, Jinxi

Yuan, Weiwei

机构：

[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Surg Oncol, Zhengzhou, Peoples R China

[2] Henan Canc Hosp, Zhengzhou, Peoples R China

[3] Zhengzhou Univ, Affiliated Hosp 3, Radiol, Zhengzhou, Peoples R China

[4] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Radiol, Zhengzhou, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16021

引用

页数：1